首頁 › 肺癌 › 俄克拉荷馬州 › Oklahoma City
Oklahoma City, OK 的 肺癌 臨床試驗
19 項針對 肺癌 的研究正在 Oklahoma City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- University of Oklahoma Health Sciences Center, Oklahoma City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
招募中3 期
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Oklahoma, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Mercy Hospital Oklahoma City, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- University of Oklahoma, Oklahoma City
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
招募中觀察性研究歡迎健康志工
- Site 101, Oklahoma City
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
招募中1 期
- Xencor Investigative Site, Oklahoma City
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
招募中1/2 期
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
招募中觀察性研究
- Hightower Clinical, Oklahoma City
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Nashville, TN40 項研究
- Baltimore, MD40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
Oklahoma City 的其他研究
- 非小細胞肺癌28 項研究
- 卵巢癌28 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌22 項研究
- 前列腺癌21 項研究
- 乳癌17 項研究
- 轉移性癌症16 項研究
- 癌症（所有類型）14 項研究
- 急性髓系白血病14 項研究
- 頭頸部鱗狀細胞癌13 項研究
- 膀胱癌11 項研究
- 胰臟癌11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。